Serological Evaluation of Onchocerciasis and Lymphatic Filariasis Elimination in the Bakoye and Falémé Foci, Mali.
Mali
elimination
lymphatic filariasis
onchocerciasis
serological monitoring
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
04 05 2021
04 05 2021
Historique:
received:
17
10
2019
pubmed:
25
3
2020
medline:
21
5
2021
entrez:
25
3
2020
Statut:
ppublish
Résumé
Ivermectin-based onchocerciasis elimination, reported in 2009-2012, for Bakoye and Falémé, Mali, supported policy-shifting from morbidity control to elimination of transmission (EOT). These foci are coendemic with lymphatic filariasis (LF). In 2007-2016 mass ivermectin plus albendazole administration was implemented. We report Ov16 (onchocerciasis) and Wb123 (LF) seroprevalence after 24-25 years of treatment to determine if onchocerciasis EOT and LF elimination as a public health problem (EPHP) have been achieved. The SD Bioline Onchocerciasis/LF Ig[immunoglobulin]G4 biplex rapid diagnostic test (RDT) was used in 2186 children aged 3-10 years in 13 villages (plus 2 hamlets) in Bakoye and in 2270 children in 15 villages (plus 1 hamlet) in Falémé. In Bakoye, all-age serosurveys were conducted in 3 historically hyperendemic villages (1867 individuals aged 3 -78 years). In Bakoye, IgG4 seropositivity was 0.27% (95% confidence interval [CI] = .13%-.60%) for both Ov16 and Wb123 antigens. In Falémé, Ov16 and Wb123 seroprevalence was 0.04% (95% CI = .01%-.25%) and 0.09% (95% CI = .02%-.32%), respectively. Ov16-seropositive children were from historically meso/hyperendemic villages. Ov16 positivity was <2% in ≤14 year-olds, and 16% in ≥40 year-olds. Wb123 seropositivity was <2% in ≤39 year-olds, reaching 3% in ≥40 year-olds. Notwithstanding uncertainty in the biplex RDT sensitivity, Ov16 and Wb123 seroprevalence among children in Bakoye and Falémé is consistent with EOT (onchocerciasis) and EPHP (LF) since stopping treatment in 2016. The few Ov16-seropositive children should be skin-snip polymerase chain reaction tested and followed up.
Sections du résumé
BACKGROUND
Ivermectin-based onchocerciasis elimination, reported in 2009-2012, for Bakoye and Falémé, Mali, supported policy-shifting from morbidity control to elimination of transmission (EOT). These foci are coendemic with lymphatic filariasis (LF). In 2007-2016 mass ivermectin plus albendazole administration was implemented. We report Ov16 (onchocerciasis) and Wb123 (LF) seroprevalence after 24-25 years of treatment to determine if onchocerciasis EOT and LF elimination as a public health problem (EPHP) have been achieved.
METHODS
The SD Bioline Onchocerciasis/LF Ig[immunoglobulin]G4 biplex rapid diagnostic test (RDT) was used in 2186 children aged 3-10 years in 13 villages (plus 2 hamlets) in Bakoye and in 2270 children in 15 villages (plus 1 hamlet) in Falémé. In Bakoye, all-age serosurveys were conducted in 3 historically hyperendemic villages (1867 individuals aged 3 -78 years).
RESULTS
In Bakoye, IgG4 seropositivity was 0.27% (95% confidence interval [CI] = .13%-.60%) for both Ov16 and Wb123 antigens. In Falémé, Ov16 and Wb123 seroprevalence was 0.04% (95% CI = .01%-.25%) and 0.09% (95% CI = .02%-.32%), respectively. Ov16-seropositive children were from historically meso/hyperendemic villages. Ov16 positivity was <2% in ≤14 year-olds, and 16% in ≥40 year-olds. Wb123 seropositivity was <2% in ≤39 year-olds, reaching 3% in ≥40 year-olds.
CONCLUSIONS
Notwithstanding uncertainty in the biplex RDT sensitivity, Ov16 and Wb123 seroprevalence among children in Bakoye and Falémé is consistent with EOT (onchocerciasis) and EPHP (LF) since stopping treatment in 2016. The few Ov16-seropositive children should be skin-snip polymerase chain reaction tested and followed up.
Identifiants
pubmed: 32206773
pii: 5811165
doi: 10.1093/cid/ciaa318
pmc: PMC8096229
doi:
Substances chimiques
Ivermectin
70288-86-7
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1585-1593Subventions
Organisme : FIC NIH HHS
ID : D43 TW008652
Pays : United States
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom
Organisme : Intramural NIH HHS
ID : Z01 AI001063
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Epidemics. 2017 Mar;18:4-15
pubmed: 28279455
Bull World Health Organ. 1986;64(5):667-81
pubmed: 3492300
Clin Vaccine Immunol. 2015 Aug;22(8):896-901
pubmed: 26018537
Adv Parasitol. 2006;61:349-94
pubmed: 16735169
PLoS Negl Trop Dis. 2012;6(3):e1574
pubmed: 22448294
Int Health. 2018 Mar 1;10(suppl_1):i7-i13
pubmed: 29471338
Parasit Vectors. 2019 Jan 15;12(1):34
pubmed: 30646934
Int Health. 2018 Mar 1;10(suppl_1):i33-i39
pubmed: 29471345
PLoS Negl Trop Dis. 2019 Dec 5;13(12):e0007557
pubmed: 31805049
Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15265-70
pubmed: 16217028
Bull Soc Pathol Exot. 1994;87(4):278-82
pubmed: 7866050
Acta Trop. 2017 Feb;166:96-105
pubmed: 27845063
Med Trop (Mars). 1978 Jan-Feb;38(1):43-51
pubmed: 723550
Parasit Vectors. 2013 Feb 22;6:39
pubmed: 23433078
Am J Trop Med Hyg. 2018 Jan;98(1):15-20
pubmed: 29165213
PLoS Negl Trop Dis. 2016 Dec 7;10(12):e0005198
pubmed: 27926918
PLoS One. 2013 Jul 23;8(7):e69231
pubmed: 23935960
Int Health. 2018 Mar 1;10(suppl_1):i20-i26
pubmed: 29471336
PLoS Negl Trop Dis. 2012;6(9):e1825
pubmed: 23029586
PLoS Negl Trop Dis. 2018 Mar 15;12(3):e0006249
pubmed: 29543797
PLoS Negl Trop Dis. 2014 Nov 13;8(11):e3281
pubmed: 25393404
Am J Epidemiol. 2019 Sep 1;188(9):1723-1732
pubmed: 31062838
Philos Trans R Soc Lond B Biol Sci. 1999 Apr 29;354(1384):809-26
pubmed: 10365406
PLoS Negl Trop Dis. 2009 Jul 21;3(7):e497
pubmed: 19621091
Trends Parasitol. 2019 Nov;35(11):860-869
pubmed: 31506245
PLoS Negl Trop Dis. 2019 Jan 30;13(1):e0007064
pubmed: 30699120
Am J Trop Med Hyg. 2017 Sep;97(3):673-676
pubmed: 28722619